FROI now retitled PharmaRoth Labs. New name.New Ticker: ROTH. And it's a non-SEC filing dark Pinky stinky.
Same old pump and dump scam, though.
Dark, dark, dark:
"FROI Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-53337
FERO INDUSTRIES, INC.
(Exact name of registrant as specified in its charter)
c/o Kane Kessler, P.C.
1350 Avenue of the Americas, New York, NY 10019
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) [ ]
Rule 12g-4(a)(2) [X]
Rule 12h-3(b)(1)(i) [ ]
Rule 12h-3(b)(1)(ii) [X]
Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or notice date: 12
Pursuant to the requirements of the Securities Exchange Act of 1934, Fero Industries, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
FERO INDUSTRIES, INC.
Date: December 31, 2012 By: Luis Manuel Ornelas Lopez
Name: Luis Manuel Ornelas Lopez
Title: President and Chief Executive Officer
Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature."
REAL DUE DILLIGENCE BELOW
PHARMAROTH LABS, INC. (OTC: ROTH)
PharmaRoth Labs Inc. (OTC: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and other exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, a oral treatment for Type II diabetes.
July 23, 2014
PharmaRoth Labs, Inc. Announces New Distribution Agreement in China
April 16, 2014
PharmaRoth Labs, Inc. Announces Mexican Distributor Surpasses Sales Goal
March 24, 2014
PharmaRoth Labs, Inc. Announces Retails and Wholesale Distribution Channels in Mexico
March 17, 2014
PharmaRoth Labs, Inc. Announces Results From FDA Application
Stock Transfer Agent:
Pacific Stock Transfer
4045 S. Spencer Street
Las Vegas, NV 89119
| || |
Sucanon®...Diabetes is not curable but is treatable...enjoy life
What is Sucanon®?:
Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
| || |
1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose 2. Sucanon® increases the binding of insulin to its receptors 3. Sucanon® increases the internalization of insulin 4. As a result, Sucanon® increases the intracellular level of insulin, which then increases the uptake of glucose.
Sucanon® is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels. Type II Diabetics produce insulin, but their cells gradually lose the ability to absorb and use insulin, to get sugar out of the blood stream. Sucanon® transports sugar out of the blood stream and into cells where it can be burned. Sucanon® particularly helps muscle cells use insulin and thus draw sugar out of the blood stream.
Sucanon® increases sensitivity to insulin which leads to decreased blood sugar levels and a reduction of a wide range of Type II Diabetes symptoms, including: weight gain, fatigue, excess thirst and excess urination. The reduction in blood sugar levels also reduces the possibility of peripheral nerve damage; the damage caused to peripheral nerves by chronic high blood sugar can ultimately lead to impotence in men and amputation of limbs in both men and women.
Company Updated Profile Contact Info 8250 W. Charleston Blvd
Las Vegas, NV 89117 Website: http://www.pharmaroth.com Phone: 702-544-0195
Email: email@example.com Business Description PharmaRoth Labs, Inc. is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon(R), an oral treatment for Type-II diabetes. Sucanon(R) is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon(R) globally. ROTH Security Details Share Structure
| ||Market Value1 ||$1,238,958 ||a/o Apr 27, 2015 |
| ||Authorized Shares ||500,000,000 ||a/o Oct 01, 2014 |
| ||Outstanding Shares ||317,681,637 ||a/o Mar 12, 2015 |
| ||-Restricted ||Not Available || |
| ||-Unrestricted ||Not Available || |
| ||Held at DTC ||Not Available || |
| ||Float ||124,850,000 ||a/o Jan 22, 2014 |
| ||Par Value ||0.001 || |
|Shareholders of Record ||1,019 ||a/o Jan 22, 2014 |